{"id":27388,"date":"2016-08-03T17:48:01","date_gmt":"2016-08-03T15:48:01","guid":{"rendered":"http:\/\/www.fedaiisf.it\/?p=27388"},"modified":"2016-08-03T18:33:15","modified_gmt":"2016-08-03T16:33:15","slug":"pfizer-paga-486-milioni-di-dollari-per-chiudere-la-causa-su-celebrex-e-bextra","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/pfizer-paga-486-milioni-di-dollari-per-chiudere-la-causa-su-celebrex-e-bextra\/","title":{"rendered":"PFIZER Pays $486 Million to Settle Celebrex and Bextra Lawsuit"},"content":{"rendered":"<p><img loading=\"lazy\" decoding=\"async\" class=\"alignleft\" src=\"http:\/\/www.painsite.co.nz\/media\/9197\/celebrex-packaging_646x312.jpg\" alt=\"\" width=\"375\" height=\"181\" \/>Pfizer Inc will pay <strong>486 million dollars<\/strong> to close the case in which it was accused of causing huge losses to shareholders through the<strong>concealment of security risks<\/strong> related to drugs <strong>Celebrex and Bextra<\/strong>. The two medicines were used by millions of patients suffering from <strong>osteoarthritis and rheumatoid arthritis<\/strong> For <strong>relieve pain<\/strong> but they had revealed a <strong>increased risk of heart attack or stroke<\/strong>.<\/p>\n<p>The agreement, anticipated by Reuters is subject to negotiation and would make it possible to put an end to more than <strong>11 years of litigation<\/strong> against the drug company and several officials, including former CEO Henry McKinnell.<br \/>\nIn September 2009 Pfizer <strong>had paid $2.3 billion<\/strong> after the US government investigation into the marketing of Bextra and other medicines.<\/p>\n<p>&quot;This solution reflects the company&#039;s desire to avoid the distraction of ongoing litigation and to focus on the needs of patients and physicians,&quot; Pfizer said in a statement.<\/p>\n<p>The lawsuit concerns those who bought shares <strong>between October 31, 2000 and October 19, 2005<\/strong>.<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignright\" src=\"http:\/\/img.timeinc.net\/time\/photoessays\/2009\/top10_recalls\/top10_recalls_vioxx.jpg\" alt=\"\" width=\"210\" height=\"137\" \/>Shareholders have accused Pfizer of withholding evidence that <strong>since 1998 they have been suggesting risks<\/strong> for the health of Celebrex and Bextra.<\/p>\n<p>Security concerns have surfaced <strong>at the end of 2004<\/strong>, when the rival <strong>Merck &amp; Co. has recalled its drug Vioxx<\/strong> due to the associated cardiovascular risks. Pfizer withdrew Bextra from the US market the following April.<\/p>\n<p><span class=\"vw-post-author\"><a class=\"author-name\" href=\"https:\/\/www.testmagazine.it\/author\/anna-gabriela-pulce\/\" target=\"_blank\" rel=\"author noopener\">ANNA GABRIELA FLEA<\/a> <\/span><span class=\"vw-post-meta-separator\">\u00b7<\/span> <a href=\"https:\/\/www.testmagazine.it\/2016\/08\/03\/pfizer-paga-486-milioni-di-dollari-per-chiudere-la-causa-su-celebrex-e-bextra\/11487\/\" target=\"_blank\" rel=\"noopener\"><span style=\"color: #0000ff;\"><time datetime=\"2016-08-03T14:48:56+00:00\">3 AUGUST 2016 \u2013 Test magazine<\/time><\/span><\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Pfizer Inc pagher\u00e0 486 milioni di dollari per chiudere il contenzioso che la vedeva imputata di aver causato enormi perdite per gli azionisti attraverso l\u2019occultamento dei rischi per la sicurezza connessi ai farmaci Celebrex e Bextra. I due medicinali erano utilizzati da milioni di pazienti sofferenti di osteoartrosi e artride reumatoide per alleviare il dolore &hellip;<\/p>","protected":false},"author":4,"featured_media":737,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[46,22],"class_list":["post-27388","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizie","tag-pfizer","tag-truffa-farmaci"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/27388","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=27388"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/27388\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/737"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=27388"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=27388"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=27388"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}